Exact Mass: 451.1756646
Exact Mass Matches: 451.1756646
Found 152 metabolites which its exact mass value is equals to given mass value 451.1756646
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Doxazosin
Doxazosin is a quinazoline-derivative that selectively antagonizes postsynaptic α1-adrenergic receptors. It may be used to mild to moderate hypertension and in the management of symptomatic benign prostatic hyperplasia (BPH). α1-Receptors mediate contraction and hypertrophic growth of smooth muscle cells. Antagonism of these receptors leads to smooth muscle relaxation in the peripheral vasculature and prostate gland. C - Cardiovascular system > C02 - Antihypertensives > C02C - Antiadrenergic agents, peripherally acting > C02CA - Alpha-adrenoreceptor antagonists C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
4-Amino-5-chloro-N-[(3S,4R)-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl]-2-hydroxybenzamide
C22H27ClFN3O4 (451.16740240000007)
4-Hydroxypropranolol glucuronide
C22H29NO9 (451.18422240000007)
Succinyl-trialanine-4-nitroanilide
(2S)-2-((3-((4-(4-Fluorophenoxy)phenyl)methylcarbamoyl)-4-methoxy-phenyl)methyl)butanoic acid
C26H26FNO5 (451.17949180000005)
Pseudolycorine-1-O-beta-D-glucoside
C22H29NO9 (451.18422240000007)
(1S,4R)-1-(beta-D-Glucopyranosyloxy)-4-(6-deoxy-beta-D-gulopyranosyloxy)-2-cyclopentene-1-carboxamide
C18H29NO12 (451.16896740000004)
doxazosin
C - Cardiovascular system > C02 - Antihypertensives > C02C - Antiadrenergic agents, peripherally acting > C02CA - Alpha-adrenoreceptor antagonists C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS CONFIDENCE standard compound; EAWAG_UCHEM_ID 3293
Ala Cys Cys Arg
Ala Cys Arg Cys
Ala Arg Cys Cys
Cys Ala Cys Arg
Cys Ala Arg Cys
Cys Cys Ala Arg
Cys Cys Arg Ala
Cys Asp Lys Ser
C16H29N5O8S (451.17367540000004)
Cys Asp Ser Lys
C16H29N5O8S (451.17367540000004)
Cys Lys Asp Ser
C16H29N5O8S (451.17367540000004)
Cys Lys Ser Asp
C16H29N5O8S (451.17367540000004)
Cys Gln Thr Thr
C16H29N5O8S (451.17367540000004)
Cys Arg Ala Cys
Cys Arg Cys Ala
Cys Arg Ser Ser
C15H29N7O7S (451.18490840000004)
Cys Ser Asp Lys
C16H29N5O8S (451.17367540000004)
Cys Ser Lys Asp
C16H29N5O8S (451.17367540000004)
Cys Ser Arg Ser
C15H29N7O7S (451.18490840000004)
Cys Ser Ser Arg
C15H29N7O7S (451.18490840000004)
Cys Thr Gln Thr
C16H29N5O8S (451.17367540000004)
Cys Thr Thr Gln
C16H29N5O8S (451.17367540000004)
Asp Cys Lys Ser
C16H29N5O8S (451.17367540000004)
Asp Cys Ser Lys
C16H29N5O8S (451.17367540000004)
Asp Phe Gly Asn
Asp Phe Asn Gly
Asp Gly Phe Asn
Asp Gly Asn Phe
Asp Lys Cys Ser
C16H29N5O8S (451.17367540000004)
Asp Lys Ser Cys
C16H29N5O8S (451.17367540000004)
Asp Asn Phe Gly
Asp Asn Gly Phe
Asp Ser Cys Lys
C16H29N5O8S (451.17367540000004)
Asp Ser Lys Cys
C16H29N5O8S (451.17367540000004)
Phe Asp Gly Asn
Phe Asp Asn Gly
Phe Gly Asp Asn
Phe Gly Asn Asp
Phe Asn Asp Gly
Phe Asn Gly Asp
Gly Asp Phe Asn
Gly Asp Asn Phe
Gly Phe Asp Asn
Gly Phe Asn Asp
Gly Asn Asp Phe
Gly Asn Phe Asp
Lys Cys Asp Ser
C16H29N5O8S (451.17367540000004)
Lys Cys Ser Asp
C16H29N5O8S (451.17367540000004)
Lys Asp Cys Ser
C16H29N5O8S (451.17367540000004)
Lys Asp Ser Cys
C16H29N5O8S (451.17367540000004)
Lys Ser Cys Asp
C16H29N5O8S (451.17367540000004)
Lys Ser Asp Cys
C16H29N5O8S (451.17367540000004)
Met Asn Ser Thr
C16H29N5O8S (451.17367540000004)
Met Asn Thr Ser
C16H29N5O8S (451.17367540000004)
Met Gln Ser Ser
C16H29N5O8S (451.17367540000004)
Met Ser Asn Thr
C16H29N5O8S (451.17367540000004)
Met Ser Gln Ser
C16H29N5O8S (451.17367540000004)
Met Ser Ser Gln
C16H29N5O8S (451.17367540000004)
Met Ser Thr Asn
C16H29N5O8S (451.17367540000004)
Met Thr Asn Ser
C16H29N5O8S (451.17367540000004)
Met Thr Ser Asn
C16H29N5O8S (451.17367540000004)
Asn Asp Phe Gly
Asn Asp Gly Phe
Asn Phe Asp Gly
Asn Phe Gly Asp
Asn Gly Asp Phe
Asn Gly Phe Asp
Asn Met Ser Thr
C16H29N5O8S (451.17367540000004)
Asn Met Thr Ser
C16H29N5O8S (451.17367540000004)
Asn Ser Met Thr
C16H29N5O8S (451.17367540000004)
Asn Ser Thr Met
C16H29N5O8S (451.17367540000004)
Asn Thr Met Ser
C16H29N5O8S (451.17367540000004)
Asn Thr Ser Met
C16H29N5O8S (451.17367540000004)
Gln Cys Thr Thr
C16H29N5O8S (451.17367540000004)
Gln Met Ser Ser
C16H29N5O8S (451.17367540000004)
Gln Ser Met Ser
C16H29N5O8S (451.17367540000004)
Gln Ser Ser Met
C16H29N5O8S (451.17367540000004)
Gln Thr Cys Thr
C16H29N5O8S (451.17367540000004)
Gln Thr Thr Cys
C16H29N5O8S (451.17367540000004)
Arg Ala Cys Cys
Arg Cys Ala Cys
Arg Cys Cys Ala
Arg Cys Ser Ser
C15H29N7O7S (451.18490840000004)
Arg Ser Cys Ser
C15H29N7O7S (451.18490840000004)
Arg Ser Ser Cys
C15H29N7O7S (451.18490840000004)
Ser Cys Asp Lys
C16H29N5O8S (451.17367540000004)
Ser Cys Lys Asp
C16H29N5O8S (451.17367540000004)
Ser Cys Arg Ser
C15H29N7O7S (451.18490840000004)
Ser Cys Ser Arg
C15H29N7O7S (451.18490840000004)
Ser Asp Cys Lys
C16H29N5O8S (451.17367540000004)
Ser Asp Lys Cys
C16H29N5O8S (451.17367540000004)
Ser Lys Cys Asp
C16H29N5O8S (451.17367540000004)
Ser Lys Asp Cys
C16H29N5O8S (451.17367540000004)
Ser Met Asn Thr
C16H29N5O8S (451.17367540000004)
Ser Met Gln Ser
C16H29N5O8S (451.17367540000004)
Ser Met Ser Gln
C16H29N5O8S (451.17367540000004)
Ser Met Thr Asn
C16H29N5O8S (451.17367540000004)
Ser Asn Met Thr
C16H29N5O8S (451.17367540000004)
Ser Asn Thr Met
C16H29N5O8S (451.17367540000004)
Ser Gln Met Ser
C16H29N5O8S (451.17367540000004)
Ser Gln Ser Met
C16H29N5O8S (451.17367540000004)
Ser Arg Cys Ser
C15H29N7O7S (451.18490840000004)
Ser Arg Ser Cys
C15H29N7O7S (451.18490840000004)
Ser Ser Cys Arg
C15H29N7O7S (451.18490840000004)
Ser Ser Met Gln
C16H29N5O8S (451.17367540000004)
Ser Ser Gln Met
C16H29N5O8S (451.17367540000004)
Ser Ser Arg Cys
C15H29N7O7S (451.18490840000004)
Ser Thr Met Asn
C16H29N5O8S (451.17367540000004)
Ser Thr Asn Met
C16H29N5O8S (451.17367540000004)
Thr Cys Gln Thr
C16H29N5O8S (451.17367540000004)
Thr Cys Thr Gln
C16H29N5O8S (451.17367540000004)
Thr Met Asn Ser
C16H29N5O8S (451.17367540000004)
Thr Met Ser Asn
C16H29N5O8S (451.17367540000004)
Thr Asn Met Ser
C16H29N5O8S (451.17367540000004)
Thr Asn Ser Met
C16H29N5O8S (451.17367540000004)
Thr Gln Cys Thr
C16H29N5O8S (451.17367540000004)
Thr Gln Thr Cys
C16H29N5O8S (451.17367540000004)
Thr Ser Met Asn
C16H29N5O8S (451.17367540000004)
Thr Ser Asn Met
C16H29N5O8S (451.17367540000004)
Thr Thr Cys Gln
C16H29N5O8S (451.17367540000004)
Thr Thr Gln Cys
C16H29N5O8S (451.17367540000004)
4-methylumbelliferyl a-l-idopyranosiduronic acid, cyclohexylammonium salt
C22H29NO9 (451.18422240000007)
Dihydrocodeine bitartrate
C22H29NO9 (451.18422240000007)
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D002491 - Central Nervous System Agents > D000700 - Analgesics
2-{4-[2-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-D]pyrimidin-5-YL)-ethyl]-benzoylamino}-4-(2H-tetrazol-5-YL)-butyric acid
C20H21N9O4 (451.17164260000004)
4-Amino-5-chloro-N-[(3S,4R)-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl]-2-hydroxybenzamide
C22H27ClFN3O4 (451.16740240000007)
(2S)-2-((3-((4-(4-Fluorophenoxy)phenyl)methylcarbamoyl)-4-methoxy-phenyl)methyl)butanoic acid
C26H26FNO5 (451.17949180000005)
7-{2-Hydroxy-3-[(naphthalen-1-yl)oxy]propyl}-3-methyl-8-(morpholin-4-yl)-3,7-dihydropurine-2,6-dione
PRGL493
PRGL493 is a potent and selective long-chain acyl-CoA synthetase 4 (ACSL4) inhibitor. PRGL493 blocks cell proliferation and tumor growth in both breast and prostate cellular and animal models. PRGL493 is used for cancer research[1].
(2r,3s,4s,5r,6s)-2-{[(1r,14s,15s,16s)-4,14-dihydroxy-5-methoxy-9-azatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-2(7),3,5,12-tetraen-15-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
C22H29NO9 (451.18422240000007)